Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

NAD+ homeostasis in renal health and disease.

Ralto KM, Rhee EP, Parikh SM.

Nat Rev Nephrol. 2019 Oct 31. doi: 10.1038/s41581-019-0216-6. [Epub ahead of print] Review.

PMID:
31673160
2.

Proteomics and Metabolomics in Kidney Disease, including Insights into Etiology, Treatment, and Prevention.

Dubin RF, Rhee EP.

Clin J Am Soc Nephrol. 2019 Oct 21. pii: CJN.07420619. doi: 10.2215/CJN.07420619. [Epub ahead of print]

PMID:
31636087
3.

Author Correction: Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury.

Zhou HL, Zhang R, Anand P, Stomberski CT, Qian Z, Hausladen A, Wang L, Rhee EP, Parikh SM, Karumanchi SA, Stamler JS.

Nature. 2019 Jun;570(7759):E23. doi: 10.1038/s41586-019-1225-0.

PMID:
31089212
4.

Serum Metabolites and Cardiac Death in Patients on Hemodialysis.

Hu JR, Grams ME, Coresh J, Hwang S, Kovesdy CP, Guallar E, Rhee EP, Shafi T.

Clin J Am Soc Nephrol. 2019 May 7;14(5):747-749. doi: 10.2215/CJN.12691018. Epub 2019 Apr 8. No abstract available.

PMID:
30962187
5.

Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort.

Titan SM, Venturini G, Padilha K, Goulart AC, Lotufo PA, Bensenor IJ, Krieger JE, Thadhani RI, Rhee EP, Pereira AC.

PLoS One. 2019 Mar 18;14(3):e0213764. doi: 10.1371/journal.pone.0213764. eCollection 2019.

6.

1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics.

Tavares G, Venturini G, Padilha K, Zatz R, Pereira AC, Thadhani RI, Rhee EP, Titan SMO.

Metabolomics. 2018 Feb 27;14(4):39. doi: 10.1007/s11306-018-1337-9.

PMID:
30830377
7.

Polyunsaturated Fatty Acid Desaturation Is a Mechanism for Glycolytic NAD+ Recycling.

Kim W, Deik A, Gonzalez C, Gonzalez ME, Fu F, Ferrari M, Churchhouse CL, Florez JC, Jacobs SBR, Clish CB, Rhee EP.

Cell Metab. 2019 Apr 2;29(4):856-870.e7. doi: 10.1016/j.cmet.2018.12.023. Epub 2019 Jan 24.

PMID:
30686744
8.

Variability of Two Metabolomic Platforms in CKD.

Rhee EP, Waikar SS, Rebholz CM, Zheng Z, Perichon R, Clish CB, Evans AM, Avila J, Denburg MR, Anderson AH, Vasan RS, Feldman HI, Kimmel PL, Coresh J; CKD Biomarkers Consortium.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):40-48. doi: 10.2215/CJN.07070618. Epub 2018 Dec 20.

PMID:
30573658
9.

Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury.

Zhou HL, Zhang R, Anand P, Stomberski CT, Qian Z, Hausladen A, Wang L, Rhee EP, Parikh SM, Karumanchi SA, Stamler JS.

Nature. 2019 Jan;565(7737):96-100. doi: 10.1038/s41586-018-0749-z. Epub 2018 Nov 28. Erratum in: Nature. 2019 Jun;570(7759):E23.

10.

Metabolites related to eGFR: Evaluation of candidate molecules for GFR estimation using untargeted metabolomics.

Titan SM, Venturini G, Padilha K, Tavares G, Zatz R, Bensenor I, Lotufo PA, Rhee EP, Thadhani RI, Pereira AC.

Clin Chim Acta. 2019 Feb;489:242-248. doi: 10.1016/j.cca.2018.08.037. Epub 2018 Aug 25.

PMID:
30153452
11.

Elevated lipoxygenase and cytochrome P450 products predict progression of chronic kidney disease.

Afshinnia F, Zeng L, Byun J, Wernisch S, Deo R, Chen J, Hamm L, Miller ER, Rhee EP, Fischer MJ, Sharma K, Feldman HI, Michailidis G, Pennathur S; CRIC Study Investigators .

Nephrol Dial Transplant. 2018 Jul 25. doi: 10.1093/ndt/gfy232. [Epub ahead of print]

PMID:
30137494
12.

De novo NAD+ biosynthetic impairment in acute kidney injury in humans.

Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J, Lerner A, Kher A, Kim SH, Khoury CC, Herzig SJ, Trovato ME, Simon-Tillaux N, Lynch MR, Thadhani RI, Clish CB, Khabbaz KR, Rhee EP, Waikar SS, Berg AH, Parikh SM.

Nat Med. 2018 Sep;24(9):1351-1359. doi: 10.1038/s41591-018-0138-z. Epub 2018 Aug 20.

13.

Metabolomics Research in Chronic Kidney Disease.

Grams ME, Shafi T, Rhee EP.

J Am Soc Nephrol. 2018 Jun;29(6):1588-1590. doi: 10.1681/ASN.2018030256. Epub 2018 May 3. No abstract available.

14.

A Systems-Level View of Renal Metabolomics.

Rhee EP.

Semin Nephrol. 2018 Mar;38(2):142-150. doi: 10.1016/j.semnephrol.2018.01.005. Review.

15.

How Omics Data Can Be Used in Nephrology.

Rhee EP.

Am J Kidney Dis. 2018 Jul;72(1):129-135. doi: 10.1053/j.ajkd.2017.12.008. Epub 2018 Feb 23. Review.

16.

Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities.

Christov M, Clark AR, Corbin B, Hakroush S, Rhee EP, Saito H, Brooks D, Hesse E, Bouxsein M, Galjart N, Jung JY, Mundel P, Jüppner H, Weins A, Greka A.

JCI Insight. 2018 Feb 22;3(4). pii: 95091. doi: 10.1172/jci.insight.95091. eCollection 2018 Feb 22.

17.

Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.

Kalim S, Wald R, Yan AT, Goldstein MB, Kiaii M, Xu D, Berg AH, Clish C, Thadhani R, Rhee EP, Perl J.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):436-444. doi: 10.2215/CJN.08790817. Epub 2018 Feb 14.

18.

Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.

Elmariah S, Farrell LA, Furman D, Lindman BR, Shi X, Morningstar JE, Rhee EP, Gerszten RE.

JAMA Cardiol. 2018 Mar 1;3(3):242-246. doi: 10.1001/jamacardio.2017.4873.

19.

Metabolomics and Kidney Precision Medicine.

Kalim S, Rhee EP.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1726-1727. doi: 10.2215/CJN.09480817. Epub 2017 Sep 28. No abstract available.

20.

Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort.

Afshinnia F, Rajendiran TM, Karnovsky A, Soni T, Wang X, Xie D, Yang W, Shafi T, Weir MR, He J, Brecklin CS, Rhee EP, Schelling JR, Ojo A, Feldman H, Michailidis G, Pennathur S.

Kidney Int Rep. 2016 Nov;1(4):256-268. doi: 10.1016/j.ekir.2016.08.007. Epub 2016 Aug 18. Erratum in: Kidney Int Rep. 2017 Sep 18;2(6):1265.

21.

Activation of IRF1 in Human Adipocytes Leads to Phenotypes Associated with Metabolic Disease.

Friesen M, Camahort R, Lee YK, Xia F, Gerszten RE, Rhee EP, Deo RC, Cowan CA.

Stem Cell Reports. 2017 May 9;8(5):1164-1173. doi: 10.1016/j.stemcr.2017.03.014. Epub 2017 Apr 13.

22.

Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association.

Cheng S, Shah SH, Corwin EJ, Fiehn O, Fitzgerald RL, Gerszten RE, Illig T, Rhee EP, Srinivas PR, Wang TJ, Jain M; American Heart Association Council on Functional Genomics and Translational Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council.

Circ Cardiovasc Genet. 2017 Apr;10(2). pii: e000032. doi: 10.1161/HCG.0000000000000032. Review.

23.

Urinary metabolites along with common and rare genetic variations are associated with incident chronic kidney disease.

McMahon GM, Hwang SJ, Clish CB, Tin A, Yang Q, Larson MG, Rhee EP, Li M; CKDGen Consortium, Levy D, O'Donnell CJ, Coresh J, Young JH, Gerszten RE, Fox CS.

Kidney Int. 2017 Jun;91(6):1426-1435. doi: 10.1016/j.kint.2017.01.007. Epub 2017 Mar 14.

PMID:
28302371
24.

An overview of renal metabolomics.

Kalim S, Rhee EP.

Kidney Int. 2017 Jan;91(1):61-69. doi: 10.1016/j.kint.2016.08.021. Epub 2016 Sep 28. Review.

25.

An exome array study of the plasma metabolome.

Rhee EP, Yang Q, Yu B, Liu X, Cheng S, Deik A, Pierce KA, Bullock K, Ho JE, Levy D, Florez JC, Kathiresan S, Larson MG, Vasan RS, Clish CB, Wang TJ, Boerwinkle E, O'Donnell CJ, Gerszten RE.

Nat Commun. 2016 Jul 25;7:12360. doi: 10.1038/ncomms12360.

26.

Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study.

Rhee EP, Clish CB, Wenger J, Roy J, Elmariah S, Pierce KA, Bullock K, Anderson AH, Gerszten RE, Feldman HI.

Am J Nephrol. 2016;43(5):366-74. doi: 10.1159/000446484. Epub 2016 May 13.

27.

Metabolite Profiles Predict Acute Kidney Injury and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement.

Elmariah S, Farrell LA, Daher M, Shi X, Keyes MJ, Cain CH, Pomerantsev E, Vlahakes GJ, Inglessis I, Passeri JJ, Palacios IF, Fox CS, Rhee EP, Gerszten RE.

J Am Heart Assoc. 2016 Mar 15;5(3):e002712. doi: 10.1161/JAHA.115.002712.

28.

PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection.

Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB, Stillman IE, Karumanchi SA, Rhee EP, Parikh SM.

Nature. 2016 Mar 24;531(7595):528-32. doi: 10.1038/nature17184. Epub 2016 Mar 16.

29.

Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes.

Ho JE, Larson MG, Ghorbani A, Cheng S, Chen MH, Keyes M, Rhee EP, Clish CB, Vasan RS, Gerszten RE, Wang TJ.

PLoS One. 2016 Feb 10;11(2):e0148361. doi: 10.1371/journal.pone.0148361. eCollection 2016.

30.

NADPH Oxidase 4 at the Nexus of Diabetes, Reactive Oxygen Species, and Renal Metabolism.

Rhee EP.

J Am Soc Nephrol. 2016 Feb;27(2):337-9. doi: 10.1681/ASN.2015060698. Epub 2015 Jul 22. No abstract available.

31.

Cross-sectional examination of metabolites and metabolic phenotypes in uremia.

Kalim S, Clish CB, Deferio JJ, Ortiz G, Moffet AS, Gerszten RE, Thadhani R, Rhee EP.

BMC Nephrol. 2015 Jul 7;16:98. doi: 10.1186/s12882-015-0100-y.

32.

Metabolomics and renal disease.

Rhee EP.

Curr Opin Nephrol Hypertens. 2015 Jul;24(4):371-9. doi: 10.1097/MNH.0000000000000136. Review.

33.

Renal Clearance of Mineral Metabolism Biomarkers.

van Ballegooijen AJ, Rhee EP, Elmariah S, de Boer IH, Kestenbaum B.

J Am Soc Nephrol. 2016 Feb;27(2):392-7. doi: 10.1681/ASN.2014121253. Epub 2015 Jun 5.

34.

Erratum: Distinct metabolomic signatures are associated with longevity in humans.

Cheng S, Larson MG, McCabe EL, Murabito JM, Rhee EP, Ho JE, Jacques PF, Ghorbani A, Magnusson M, Souza AL, Deik AA, Pierce KA, Bullock K, O'Donnell CJ, Melander O, Clish CB, Vasan RS, Gerszten RE, Wang TJ.

Nat Commun. 2015 May 21;6:7317. doi: 10.1038/ncomms8317. No abstract available.

PMID:
25993905
35.

Distinct metabolomic signatures are associated with longevity in humans.

Cheng S, Larson MG, McCabe EL, Murabito JM, Rhee EP, Ho JE, Jacques PF, Ghorbani A, Magnusson M, Souza AL, Deik AA, Pierce KA, Bullock K, O'Donnell CJ, Melander O, Clish CB, Vasan RS, Gerszten RE, Wang TJ.

Nat Commun. 2015 Apr 13;6:6791. doi: 10.1038/ncomms7791. Erratum in: Nat Commun. 2015;6:7317.

36.

Metabolomics of renal venous plasma from individuals with unilateral renal artery stenosis and essential hypertension.

Rhee EP, Clish CB, Pierce KA, Saad A, Lerman LO, Textor SC.

J Hypertens. 2015 Apr;33(4):836-42. doi: 10.1097/HJH.0000000000000470.

37.

Metabolite markers of incident CKD risk.

Rhee EP, Feldman HI.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1344-6. doi: 10.2215/CJN.05910614. Epub 2014 Jul 10. No abstract available.

38.

Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes.

Walford GA, Porneala BC, Dauriz M, Vassy JL, Cheng S, Rhee EP, Wang TJ, Meigs JB, Gerszten RE, Florez JC.

Diabetes Care. 2014 Sep;37(9):2508-14. doi: 10.2337/dc14-0560. Epub 2014 Jun 19.

39.

Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Pendergraft WF 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, Niles JL.

Clin J Am Soc Nephrol. 2014 Apr;9(4):736-44. doi: 10.2215/CJN.07340713. Epub 2014 Mar 13.

40.

A systematic survey of lipids across mouse tissues.

Jain M, Ngoy S, Sheth SA, Swanson RA, Rhee EP, Liao R, Clish CB, Mootha VK, Nilsson R.

Am J Physiol Endocrinol Metab. 2014 Apr 15;306(8):E854-68. doi: 10.1152/ajpendo.00371.2013. Epub 2014 Feb 11.

41.

A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.

Kalim S, Clish CB, Wenger J, Elmariah S, Yeh RW, Deferio JJ, Pierce K, Deik A, Gerszten RE, Thadhani R, Rhee EP.

J Am Heart Assoc. 2013 Dec 5;2(6):e000542. doi: 10.1161/JAHA.113.000542.

42.

2-Aminoadipic acid is a biomarker for diabetes risk.

Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, Ghorbani A, O'Sullivan J, Cheng S, Rhee EP, Sinha S, McCabe E, Fox CS, O'Donnell CJ, Ho JE, Florez JC, Magnusson M, Pierce KA, Souza AL, Yu Y, Carter C, Light PE, Melander O, Clish CB, Gerszten RE.

J Clin Invest. 2013 Oct;123(10):4309-17. doi: 10.1172/JCI64801. Epub 2013 Sep 16.

43.

Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus.

Walford GA, Davis J, Warner AS, Ackerman RJ, Billings LK, Chamarthi B, Fanelli RR, Hernandez AM, Huang C, Khan SQ, Littleton KR, Lo J, McCarthy RM, Rhee EP, Deik A, Stolerman E, Taylor A, Hudson MS, Wang TJ, Altshuler D, Grant RW, Clish CB, Gerszten RE, Florez JC.

Metabolism. 2013 Dec;62(12):1772-8. doi: 10.1016/j.metabol.2013.07.003. Epub 2013 Aug 15.

44.

A genome-wide association study of the human metabolome in a community-based cohort.

Rhee EP, Ho JE, Chen MH, Shen D, Cheng S, Larson MG, Ghorbani A, Shi X, Helenius IT, O'Donnell CJ, Souza AL, Deik A, Pierce KA, Bullock K, Walford GA, Vasan RS, Florez JC, Clish C, Yeh JR, Wang TJ, Gerszten RE.

Cell Metab. 2013 Jul 2;18(1):130-43. doi: 10.1016/j.cmet.2013.06.013.

45.

A combined epidemiologic and metabolomic approach improves CKD prediction.

Rhee EP, Clish CB, Ghorbani A, Larson MG, Elmariah S, McCabe E, Yang Q, Cheng S, Pierce K, Deik A, Souza AL, Farrell L, Domos C, Yeh RW, Palacios I, Rosenfield K, Vasan RS, Florez JC, Wang TJ, Fox CS, Gerszten RE.

J Am Soc Nephrol. 2013 Jul;24(8):1330-8. doi: 10.1681/ASN.2012101006. Epub 2013 May 16.

46.

Metabolite profiles during oral glucose challenge.

Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, Florez JC, Clish CB, Gerszten RE, Wang TJ.

Diabetes. 2013 Aug;62(8):2689-98. doi: 10.2337/db12-0754. Epub 2013 Feb 4.

47.

Metabolite profiling identifies pathways associated with metabolic risk in humans.

Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, Palma MJ, Roberts LD, Dejam A, Souza AL, Deik AA, Magnusson M, Fox CS, O'Donnell CJ, Vasan RS, Melander O, Clish CB, Gerszten RE, Wang TJ.

Circulation. 2012 May 8;125(18):2222-31. doi: 10.1161/CIRCULATIONAHA.111.067827. Epub 2012 Apr 11.

48.

Case records of the Massachusetts General Hospital. Case 4-2012. A 37-year-old man with muscle pain, weakness, and weight loss.

Rhee EP, Scott JA, Dighe AS.

N Engl J Med. 2012 Feb 9;366(6):553-60. doi: 10.1056/NEJMcpc1110051. No abstract available.

PMID:
22316449
49.

Programming human pluripotent stem cells into white and brown adipocytes.

Ahfeldt T, Schinzel RT, Lee YK, Hendrickson D, Kaplan A, Lum DH, Camahort R, Xia F, Shay J, Rhee EP, Clish CB, Deo RC, Shen T, Lau FH, Cowley A, Mowrer G, Al-Siddiqi H, Nahrendorf M, Musunuru K, Gerszten RE, Rinn JL, Cowan CA.

Nat Cell Biol. 2012 Jan 15;14(2):209-19. doi: 10.1038/ncb2411.

50.

Metabolomics and cardiovascular biomarker discovery.

Rhee EP, Gerszten RE.

Clin Chem. 2012 Jan;58(1):139-47. doi: 10.1373/clinchem.2011.169573. Epub 2011 Nov 22. Review.

Supplemental Content

Support Center